NEW
YORK, Jan. 13, 2025 /PRNewswire/ -- Baird
Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave
Ablation (MWA) technology, recently sponsored another advanced MWA
training session in New Orleans.
This program offered physicians practical experience with a
state-of-the-art treatment designed to deliver quicker recovery and
effective management of thyroid nodules.
Led by Dr. Emad Kandil, Professor
and Ellis Hanna Chair in Surgery at Tulane
University School of Medicine, the session welcomed
participation from Dr. Sean P.
Nikravan, MD, FACE, an endocrinologist based in Newport Beach, CA, and Dr. Erin H. Lin, DO, a specialist in Surgical
Oncology and General Surgery from the University of California, Irvine. Both physicians
had the opportunity to observe seven live MWA procedures, refine
advanced techniques, and evaluate the unique capabilities of this
groundbreaking technology. During the hands-on experience, they
honed precision targeting of nodules and observed the high
efficiency and quick execution of the procedure, emphasizing its
streamlined workflow and potential to enhance patient outcomes.
Following the session, Dr. Nikravan and Dr. Lin participated in
post-training discussions with Dr. Kandil, exchanging valuable
clinical insights and strategies for adopting MWA in diverse
clinical settings. Upon completing the program, both physicians
were awarded Certificates of Completion, signifying their readiness
to incorporate this advanced treatment modality into their
practice.
"Advancing the development of MWA for thyroid nodules
requires hands-on training and expert collaboration," said
Haimei Wu, Chairwoman of Baird Medical. "By supporting
specialized programs like this, we are empowering physicians with
the practical expertise needed to refine patient care and drive
broader adoption of minimally invasive thyroid treatments."
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave
ablation (MWA) technology, offering advanced treatment solutions
for conditions such as thyroid nodules, breast disease, uterine
fibroids, and liver cancer. A publicly traded company on NASDAQ,
Baird Medical is dedicated to enhancing patient care through
precision, efficiency, and safety in its innovative medical
devices. For more information, please visit
https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts and generally relate to future events or
Baird Medical's future financial or operational performance. In
some cases, you can identify forward-looking statements by
terminology such as "may," "might," "will," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue," or the negative of these terms or other
similar expressions.
These forward-looking statements are subject to risks,
uncertainties, and assumptions that could cause actual results or
outcomes to differ materially from those expressed or implied.
These statements are based on estimates and assumptions that, while
considered reasonable by Baird Medical and its management, are
inherently uncertain. Risks and uncertainties may emerge over time,
and it is not possible to anticipate all potential factors that
could affect Baird Medical's business and financial
performance.
Factors that could cause actual results to differ materially
include, but are not limited to: (1) the risk that Baird Medical
may not achieve its expansion goals in the United States, China, or other markets; (2) changes in
economic, regulatory, or market conditions that impact Baird
Medical's operations; (3) the ability to realize anticipated
benefits from ongoing business initiatives or strategic
transactions; (4) regulatory developments and compliance with
applicable laws; (5) risks related to the development,
commercialization, and market acceptance of Baird Medical's
products; and (6) other risks and uncertainties detailed in Baird
Medical's filings with the SEC.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. Baird Medical undertakes no obligation to update or
revise forward-looking statements, whether as a result of new
information, future events, or otherwise, except as required by
law. All forward-looking statements in this press release are
qualified in their entirety by this cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-sponsored-microwave-ablation-training-advances-thyroid-treatment-302348718.html
SOURCE BDMD
